Exchange: NASDAQ·Updated 07:30 PM EST

DNLI News

News
all
press releases
Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Rated "Moderate Buy" by Wall Street Analysts
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold ra...
MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Rated "Moderate Buy" by Wall Street Analysts
Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold ra...
MarketBeat
More News
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript...
SeekingAlpha
Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
Zacks
Denali Therapeutics (DNLI) delivered earnings and revenue surprises of +7.25% and +41.88%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.
Zacks
Human clinical development is putting one of aging biology’s most closely watched proteins on the biotechnology radar   New York, NY – September 30, 2026 – Klotho is quickly becoming one of the more interesting names in longevity research. What started largely as a research question around aging and biological decline is now moving closer […] The post Klotho Protein Emerges as a Potential Powerhouse In the Next Generation of Longevity Medicine appeared first on Financial News Media.
Financial News Media
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
Zacks
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
Zacks
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
Zacks

Advertisement|Remove ads.